Inovio first to advance Lassa fever candidate vaccine into a clinical trial
Inovio with CEPI announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infection from the Lassa virus. Inovio plans to enroll 60 volunteers in this placebo controlled, blinded, dose escalation study. May 21, 2019